Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneous squamous cell carcinoma and has shown clinical activity as monother...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet oncology Vol. 22; no. 6; pp. 848 - 857
Main Authors:	Stratigos, Alexander J, Sekulic, Aleksandar, Peris, Ketty, Bechter, Oliver, Prey, Sorilla, Kaatz, Martin, Lewis, Karl D, Basset-Seguin, Nicole, Chang, Anne Lynn S, Dalle, Stèphane, Orland, Almudena Fernandez, Licitra, Lisa, Robert, Caroline, Ulrich, Claas, Hauschild, Axel, Migden, Michael R, Dummer, Reinhard, Li, Siyu, Yoo, Suk-Young, Mohan, Kosalai, Coates, Ebony, Jankovic, Vladimir, Fiaschi, Nathalie, Okoye, Emmanuel, Bassukas, Ioannis D, Loquai, Carmen, De Giorgi, Vincenzo, Eroglu, Zeynep, Gutzmer, Ralf, Ulrich, Jens, Puig, Susana, Seebach, Frank, Thurston, Gavin, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Bowler, Timothy, Fury, Matthew G
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.06.2021 Elsevier Limited Elsevier
Subjects:	Adverse events Basal cell carcinoma Cancer Colitis FDA approval Hematology, Oncology, and Palliative Medicine Immunotherapy Intolerance Life Sciences Lung cancer Metastases Metastasis Monoclonal antibodies Non-small cell lung carcinoma Patients PD-1 protein Photography Radiation therapy Radiology Skin cancer Squamous cell carcinoma Statistical analysis Surgery Targeted cancer therapy Toxicity Tumors United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!